Injection vs pill: choosing between oral and injectable GLP-1s


- What the new oral GLP-1s are, in plain terms
- What the trials can and cannot tell you about pill versus shot
- The daily-pill-versus-weekly-shot trade-offs that actually matter
- Why the form factor is a physician decision, not a self-serve swap
- The questions a careful provider should answer before you start
Pills and shots now sit side by side
For the first time, a weight-management GLP-1 comes in two forms that a physician can choose between: a once-weekly injection and a once-daily pill. Both act on the GLP-1 pathway that signals fullness and slows how fast your stomach empties. What differs is how the medicine gets into you, and that single difference touches your whole routine.
What are oral Wegovy® and Foundayo™?
Oral Wegovy® is a tablet form of semaglutide from Novo Nordisk, approved by the FDA in December 2025 as the first oral GLP-1 receptor agonist approved for weight management 1. Foundayo™, the brand name for orforglipron, is a once-daily pill from Lilly, approved in April 2026 2. Both are prescription medicines for chronic weight management, and both still require a physician to prescribe and manage them.
Do the pills work as well as the shot?
Both pills were approved on the strength of large placebo-controlled trials, so a pill is a real option, not a watered-down one 34. What those trials do not give you is a head-to-head answer. The pill and shot studies enrolled different people under different conditions, so their averages cannot be lined up as a clean race. A physician can walk you through what the data mean for someone like you.
Read any trial average as a description of a crowd, not a forecast for you. Your own result could land above it or below it. That is normal, and it is exactly why the follow-up care matters more than a headline percent. A number on a chart cannot see your history, your other medications, or how your body responds in week three.
The trade-off is daily versus weekly, and timing
This is where the choice gets real. A weekly injection is one event a week. A daily pill is a small habit you repeat every morning. Neither is automatically better. They ask different things of you, and the right answer depends on how you actually live.
What does a daily pill ask of you that a weekly shot does not?
Consistency. A weekly shot is hard to forget because it is a marked event. A daily pill leans on routine, and routines slip. For some people that daily rhythm is easier than facing a needle. For others, one dose a week is the simpler ask. There is no universal winner, only the version you will actually stick with.
Timing is the other piece, and it splits the two pills apart. Oral semaglutide is taken on an empty stomach in the morning with up to 4 ounces of water, and then you wait at least 30 minutes before you eat, drink anything else, or take other oral medicines 3. That window exists because only about 1% to 2% of an oral semaglutide dose is absorbed, so the conditions have to be right 3. Orforglipron is labeled to be taken once daily with or without food 4. If a strict morning window sounds hard to keep, that difference is worth raising with your physician.
Does a pill mean no needles ever?
For these oral options, yes, no injection. That is the whole appeal for a lot of people. But removing the needle does not remove the medicine's seriousness, the side-effect profile, or the need for a clinician who is paying attention. A pill widens the door. It does not change the room you are walking into.
How the side effects compare
Mostly the same family, because the underlying pathway is shared. Oral and injectable GLP-1s tend to produce the same kind of mostly digestive effects: nausea, constipation, diarrhea, and the early-fullness feeling from a slower-emptying stomach. For many people these show up most during the climb to a higher dose, then ease. Your physician watches this and adjusts the plan. (Read more on GLP-1 side effects.)
The serious warnings apply across forms. Both labels carry a boxed warning about a risk of thyroid C-cell tumors seen in rodent studies, and both warn about pancreatitis 34. Screening for these is something a prescribing clinician does before any GLP-1 is on the table. It is not a self-assessment, and nothing in this article is a substitute for that review.

Putting the two forms side by side
A quick comparison helps, as long as you read it as a starting point for a conversation and not a verdict. The form is one variable. The care around it is the rest.
| Oral Wegovy® (semaglutide pill) | Foundayo™ (orforglipron pill) | Injectable Wegovy® (semaglutide shot) | |
|---|---|---|---|
| Form | Daily tablet | Daily tablet | Once-weekly injection |
| Maker | Novo Nordisk | Lilly | Novo Nordisk |
| FDA approval | December 2025 | April 2026 | Already established |
| Timing rules | Empty stomach, up to 4 oz water, wait 30 min | Once daily, with or without food | Weekly, any time of day |
| Side-effect family | Mostly digestive | Mostly digestive | Mostly digestive |
| Who decides the form | A licensed physician | A licensed physician | A licensed physician |
Approval dates and timing rules are from the sources listed below. Your physician decides which form, if any, is right for you. This table does not recommend a product or a dose.
What a careful provider should tell you first
The standard to demand is simple to say and rare to find. Before any form of GLP-1 is prescribed, a good provider reviews your medical history, explains the side effects honestly, sets realistic expectations, and stays reachable when the early weeks get bumpy. They also make the money clear. (See what a first GLP-1 consultation covers.)
At sipra, the cost terms are stated plainly. Recurring monthly charge until canceled. Cancel anytime in your account. No phone call required. Full cost disclosed before checkout. Nothing is charged until a physician approves. If a brand cannot give you its terms up front and in writing, that tells you something.
One more line worth holding onto. Compounded GLP-1 medications are a separate thing from these branded pills. A compounded medication is prepared by a state-licensed 503A pharmacy under a patient-specific prescription. It is a distinct compounded preparation, not a generic version of a brand and not the same as a branded product. If a provider blurs that line, treat it as a warning sign. (See how branded and compounded GLP-1s differ.)
Your next three steps
- Write down how you actually live. Do you travel a lot? Are mornings steady or chaotic? Is the needle the thing that has stopped you before? Rank what matters. This shapes the whole conversation.
- List your history. Past GLP-1 experience, other medicines, family history of thyroid or pancreatic issues. A clinician needs this to choose safely.
- Bring both to a licensed physician and decide together. The form matters. The care around it matters more. Pick a provider who will be there for the early weeks, not just the prescription. That is what sipra is for.
You do not have to settle the pill-versus-shot question on your own. The right form is the one a physician arrives at with you, and then helps you keep.
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans

From price shown is the 12-month plan rate. Prices may vary.
Frequently asked questions
Was this helpful?
Keep reading
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Weight Loss

Sources
- Novo Nordisk. "Wegovy® pill FDA approval." Company announcement. 2025. novonordisk.com
- Eli Lilly and Company. "Is Foundayo (orforglipron) approved, and is it available?" Lilly Medical. 2026. medical.lilly.com
- Novo Nordisk. "WEGOVY (semaglutide) injection and tablets, prescribing information." DailyMed, National Library of Medicine. dailymed.nlm.nih.gov
- Eli Lilly and Company. "FOUNDAYO (orforglipron) tablets, prescribing information." DailyMed, National Library of Medicine. dailymed.nlm.nih.gov